Ocular Therapeutix Q3 EPS $(0.25) Beats $(0.29) Estimate, Sales $15.08M Miss $15.25M Estimate
Portfolio Pulse from bharat@benzinga.com
Ocular Therapeutix reported Q3 losses of $(0.25) per share, beating the analyst consensus estimate of $(0.29) by 13.79%. However, the company's quarterly sales of $15.08 million missed the analyst consensus estimate of $15.25 million by 1.11%. This represents a 26.04% increase in sales compared to the same period last year.
November 07, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ocular Therapeutix's Q3 earnings beat estimates but sales missed, which may have mixed effects on the stock.
While the company's earnings beat estimates, which is generally positive for the stock, the missed sales estimates could offset this positive impact. The net effect on the stock is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100